BRIDGEWATER, N.J.—RVL Pharmaceuticals plc (Nasdaq: RVLP) announced that its FDA approved ptosis drug Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1% was selected as the winner of “Best Professional Treatment Product” in the “Shape Healthy Beauty Awards,” the annual awards conducted by Shape Magazine, out digitally and in the May issue. According to the Shape beauty team, the products selected are tested over the course of a year and determined to be the most impressive new innovations, treatment trends that work and what top tier professionals are turning to for patient solutions.

The 2022 winners include 36 products and treatments for a range of medical aesthetic conditions for the healthiest complexion, protection, skin issues, tissue tightening and lid lifting, all vetted by top skin and medical professionals.
Upneeq, oxymetazoline hydrochloride ophthalmic solution, 0.1%, received FDA approval in July 2020, introducing to the market the only non-surgical therapeutic approved for treating acquired blepharoptosis in adults. Upneeq is a safe and effective, first-in-class treatment providing patients, eyecare and now all medical aesthetic providers as of the national rollout in January 2022, a simple convenient daily drop.
In clinical trials, Upneeq demonstrated statistically significant improvements compared to vehicles in both superior visual field and eyelid lift, as measured in two pivotal double-masked efficacy and safety studies.